IMAB – I-Mab ADR
Float Short %
3.12
Margin Of Safety %
Put/Call OI Ratio
0.25
EPS Next Q Diff
0.02
EPS Last/This Y
-0.07
EPS This/Next Y
-0.05
Price
4.14
Target Price
6.67
Analyst Recom
1
Performance Q
58.53
Relative Volume
0.66
Beta
1.48
Ticker: IMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | IMAB | 4.86 | 0.22 | 0.15 | 5569 |
| 2025-08-18 | IMAB | 5.12 | 0.19 | 0.17 | 3868 |
| 2025-08-19 | IMAB | 4.27 | 0.19 | 0.32 | 3967 |
| 2025-08-20 | IMAB | 4.55 | 0.20 | 0.05 | 4285 |
| 2025-08-21 | IMAB | 4.73 | 0.19 | 0.04 | 4516 |
| 2025-08-22 | IMAB | 5.11 | 0.19 | 0.03 | 4534 |
| 2025-08-25 | IMAB | 4.78 | 0.15 | 0.07 | 6137 |
| 2025-08-26 | IMAB | 5.15 | 0.16 | 0.06 | 6535 |
| 2025-08-27 | IMAB | 4.48 | 0.16 | 0.19 | 6587 |
| 2025-08-28 | IMAB | 4.28 | 0.17 | 0.03 | 6541 |
| 2025-08-29 | IMAB | 4.16 | 0.17 | 0.03 | 6604 |
| 2025-09-02 | IMAB | 4.33 | 0.16 | 0.13 | 6935 |
| 2025-09-03 | IMAB | 4.63 | 0.16 | 0.09 | 6945 |
| 2025-09-04 | IMAB | 4.36 | 0.16 | 0.00 | 6964 |
| 2025-09-05 | IMAB | 4.41 | 0.16 | 0.07 | 6966 |
| 2025-09-08 | IMAB | 4.28 | 0.16 | 0.64 | 6952 |
| 2025-09-09 | IMAB | 4.62 | 0.17 | 0.00 | 7197 |
| 2025-09-10 | IMAB | 4.23 | 0.17 | 0.96 | 7289 |
| 2025-09-11 | IMAB | 3.95 | 0.25 | 0.00 | 8044 |
| 2025-09-12 | IMAB | 4.08 | 0.25 | 0.00 | 8058 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | IMAB | 4.85 | - | - | -0.20 |
| 2025-08-18 | IMAB | 5.09 | - | - | -0.20 |
| 2025-08-19 | IMAB | 4.21 | - | - | -0.20 |
| 2025-08-20 | IMAB | 4.49 | - | - | -0.20 |
| 2025-08-21 | IMAB | 4.72 | - | - | -0.20 |
| 2025-08-22 | IMAB | 5.18 | - | - | -0.23 |
| 2025-08-25 | IMAB | 4.80 | - | - | -0.23 |
| 2025-08-26 | IMAB | 5.18 | - | - | -0.23 |
| 2025-08-28 | IMAB | 4.25 | - | - | -0.23 |
| 2025-08-29 | IMAB | 4.16 | - | - | -0.23 |
| 2025-09-02 | IMAB | 4.32 | - | - | -0.34 |
| 2025-09-03 | IMAB | 4.64 | - | - | -0.34 |
| 2025-09-04 | IMAB | 4.35 | - | - | -0.34 |
| 2025-09-05 | IMAB | 4.38 | - | - | -0.34 |
| 2025-09-08 | IMAB | 4.27 | - | - | -0.34 |
| 2025-09-09 | IMAB | 4.61 | - | - | -0.34 |
| 2025-09-10 | IMAB | 4.22 | - | - | -0.34 |
| 2025-09-11 | IMAB | 3.90 | - | - | -0.34 |
| 2025-09-12 | IMAB | 4.14 | - | - | -0.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | IMAB | 0.00 | -35.70 | 0.80 |
| 2025-08-18 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-19 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-20 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-21 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-22 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-25 | IMAB | 0.00 | 9.81 | 0.79 |
| 2025-08-26 | IMAB | 0.00 | 9.81 | 0.79 |
| 2025-08-27 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-08-28 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-08-29 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-02 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-03 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-04 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-05 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-08 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-09 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-10 | IMAB | 0.00 | 9.81 | 2.70 |
| 2025-09-11 | IMAB | 0.00 | 9.81 | 3.12 |
| 2025-09-12 | IMAB | 0.00 | 9.81 | 3.12 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.07
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
Institutional Transactions
9.81
Beta
1.48
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
18
Sentiment Score
74
Actual DrawDown %
95.2
Max Drawdown 5-Year %
-99.3
Target Price
6.67
P/E
Forward P/E
PEG
P/S
P/B
1.65
P/Free Cash Flow
EPS
-0.71
Average EPS Est. Cur. Y
-0.34
EPS Next Y. (Est.)
-0.39
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.66
Return on Equity vs Sector %
-45.2
Return on Equity vs Industry %
-32
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.15
EBIT Estimation
I-MABSector: Healthcare
Industry: Biotechnology
Employees: 32
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
stock quote shares IMAB – I-Mab ADR Stock Price stock today
news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMAB – I-Mab ADR yahoo finance google finance
stock history IMAB – I-Mab ADR invest stock market
stock prices IMAB premarket after hours
ticker IMAB fair value insiders trading